|
Mission
Statement:
The
mission of the Foundation Fighting Blindness Clinical Research Institute
is to accelerate the translation of laboratory based research
into clinical trials for treatments and cures of retinal degenerative
diseases.
Background
of the FFB Clinical Research Institute:
The Clinical Research Institute is a newly established non-profit entity, a support
organization of the Foundation Fighting Blindness (FFB). The
mission of the FFB Clinical Research Institute is to accelerate the translation of laboratory
based research into clinical trials for treatments and cures
of retinal degenerative diseases. It is a medical research
institute that will obtain support from government agencies,
corporations and private foundations. It may also receive
royalties or licensing fees from the drug discovery processes
and commercialization of new therapies.
The
Foundation Fighting Blindness is a non-profit health foundation that has been incorporated
since 1971. Over the years FFB has invested over 140 million
dollars to provide seed money for scientific research of diseases
of the retina causing blindness.
Goals
of the Clinical Research Institute:
The goal of the Clinical Research Institute is to develop a bridge between scientific,
clinical, governmental, pharmaceutical and financial communities
to advance clinical trials of candidate pharmaceutical and
genetic therapies and delivery systems for orphan retinal
degenerative diseases (RDD’s). In this regard, the Institute wishes
to educate the scientific and clinical communities of opportunities
and processes of drug discovery.
As
a medical research institute, the FFB Clinical Research Institute will search for candidate
therapies and explore new pathogenetic pathways of retinal
diseases to further the drug discovery process.
The Institute
will raise funds to support Phase I and Phase II clinical
trials in order to expedite the commercialization of candidate
therapies for RDD patients. The Institute will also provide assistance
to the management of clinical trials and subsequent commercialization.
Executive
Summary of Symposium |
